4 completed, 1 terminated. 5 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow aluminum sulfate: new trials by email Literature Review of aluminum sulfate trials Research Report on aluminum sulfate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine, Bivalent RBD-based ARVAC-CG vaccine - COVID-19 Vaccine | Phase 2 / Phase 3 | Completed | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | 2014 | 2023-02-06 | 2023-12-22 |
| Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19) GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1, Normal saline (0.9% sodium chloride solution) - Stage 1, GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1 - COVID-19 (Healthy Volunteers) | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 260 | 2021-01-20 | 2023-04-18 |
| A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease CAD106 Immunotherapy, Placebo to CAD106, CNP520 - Alzheimers Disease | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 480 | 2015-11-30 | 2021-07-08 |
| Improving the Efficacy of Anti-Nicotine Immunotherapy NIC002 in Aluminum hydroxide (Alum), Placebo Vaccine - Aluminum hydroxide - Nicotine Dependence | Phase 2 | Completed | Alexey Mukhin | 52 | 2010-12-01 | 2014-03-05 |
| Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients CAD106, Placebo, Alum - Alzheimer's Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 177 | 2010-03-01 | 2021-03-05 |
Alzheimer Disease (2) · COVID-19 (1) · Central Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Tobacco Use Disorder (1)
Novartis Pharmaceuticals (2) · Alexey Mukhin (1) · Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno (1) · SK Bioscience Co., Ltd. (1)
United States (3) · Belgium (2) · Canada (2) · Germany (2) · Netherlands (2) · Spain (2) · Switzerland (2) · Argentina (1) · Australia (1) · Finland (1) · Italy (1) · Norway (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Alexey G Mukhin, M.D., Ph.D. (1) · Gustavo Yerino, MD (1) · Hee Jin Cheong (1)
1UF1AG046150-01 (1), 2009 (1), 2015 (1)